AUTHORS
Chengyang Xu, Xuemin Gao, MD2, Hongbin Yu3, Yi Xu Jr, PhD4, Ai Guan, MD5, Lu Zhang, M.D.6, Zhuang Tian, MD7, Qinyu Liu8, Chunlan Zhang9, Kai Sun10, Yu Wu, MD11, Kaini Shen, MD12, Jian Li, MD13
AFFILIATIONS
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 West China Hospital, Sichuan University, Chengdu, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 West China Hospital, Sichuan University, Chengdu, China
9 West China Hospital, Sichuan University, Chengdu, China
10 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 West China Hospital, Sichuan University, Chengdu, China
12 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
13 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
ABSTRACT
PURPOSE: In systemic light-chain (AL) amyloidosis, static baseline staging systems, such as the Mayo 2004 model, are crucial for initial risk assessment. However, a patient's long-term survival is dynamically driven by the subsequent depth of hematologic and organ responses. Because multi-organ responses occur at heterogeneous rates and are typically evaluated in isolation, current consensus criteria fail to provide a unified, evolving risk profile. We aimed to develop and independently validate dynamic landmark prognostic models at 6 and 12 months that bridge initial disease burden with evolving therapeutic responses to better guide mid-course survival prediction.
METHODS: We evaluated a total of 967 newly diagnosed patients with AL amyloidosis. The study was conducted with institutional review board approval and in accordance with the Declaration of Helsinki, with informed consent obtained from all patients. The study comprised an internal training cohort (n=759, from Peking Union Medical College Hospital) and an independent external validation cohort (n=208, from West China Hospital). Clinical data, incorporating baseline risk factors and updated 4-tier hematologic and multi-organ response criteria, were extracted at 6 and 12 months after treatment initiation. Landmark survival analyses were employed to eliminate immortal time bias, and backward stepwise Cox proportional hazards regression was utilized to develop integer-based risk models.
RESULTS: The resulting 6-month model integrated critical baseline characteristics (age ≥ 65 years, bone marrow plasma cells ≥ 10%, and Mayo 2004 stage II-III) alongside 6-month hematologic and cardiac responses. The 12-month model incorporated the identical baseline factors alongside 12-month hematologic, cardiac, and renal responses. Based on the integer scores, patients were effectively stratified into low-, intermediate-, and high-risk subgroups with distinct landmark overall survival in the training cohort (p < 0.001 for both models). In the independent validation cohort, both models demonstrated excellent discriminative capabilities. The 6-month model achieved a Harrell’s C-index of 0.776, and the 12-month model achieved a C-index of 0.810, both significantly outperforming the static baseline Mayo 2004 staging alone (C-index: 0.622 for both models, p < 0.001). Furthermore, dynamic longitudinal tracking revealed substantial risk migration. High-risk patients at 6 months who subsequently deepened their therapeutic responses and successfully migrated to the low-risk category by 12 months demonstrated a distinct survival advantage over those with stable high-risk disease. To facilitate seamless clinical application, a web-based risk calculator (https://amyloidosis-risk-model.com/) was deployed.
CONCLUSION: By systematically bridging persistent baseline disease burden with the granular depth of evolving multi-organ treatment responses, these independently validated 6- and 12-month landmark models offer a highly robust framework for long-term survival stratification. They effectively capture personalized disease trajectories, provide a refined tool for individualized mid-course survival predictions, and have the potential to serve as surrogate endpoints for overall survival in modern clinical trials.
DISCLOSURES
Chengyang Xu: No relevant conflicts of interest to declare.